ERBB2 and neoplasm: In conclusion, in vivo and in vitro studies demonstrated that PCC0208027 had strong anti-tumor activity on NSCLC tumors with drug-sensitive EGFR mutations, drug-resistant EGFR mutations, and HER2 amplification.